In vitro activity of A-16686, a potential antiplaque agent.

Area of Science:

• Microbiology
• Pharmacology
• Dental Science

Background:

• Dental plaque is a biofilm rich in Gram-positive bacteria, including *Streptococcus mutans*, a primary cause of dental caries.
• Existing antiplaque agents like chlorhexidine have limitations, necessitating the search for novel compounds.

Purpose of the Study:

• To evaluate the efficacy of A-16686, a novel glycoproteide antibiotic, as an antiplaque agent.
• To compare the antiplaque activity of A-16686 with established agents: chlorhexidine, benzalkonium chloride, and cetylpyridinium chloride.

Main Methods:

• In vitro susceptibility testing against clinical isolates of plaque-associated Gram-positive bacteria.
• Assessment of bactericidal activity, minimum bactericidal concentration (MBC)/minimum inhibitory concentration (MIC) ratios, and killing kinetics.
• Evaluation of A-16686's effect on in vitro plaque formation and preformed plaques.

Main Results:

• A-16686 exhibited potent activity against key plaque bacteria, including *Streptococcus mutans*, lactobacilli, *Actinomyces viscosus*, and *Actinomyces naeslundii*.
• The antibiotic demonstrated rapid bactericidal effects on *Streptococci* and *S. mutans*, with 99.9% killing within 5 minutes at 200 µg/ml.
• A-16686 effectively inhibited in vitro plaque formation and showed activity against preformed plaques, comparable to existing agents.

Conclusions:

• A-16686 is a promising antiplaque agent due to its narrow spectrum, rapid bactericidal action, and lack of cross-resistance with existing antibiotics.
• Favorable attributes including non-oral absorption, good mucosal tolerability, and suitable physical characteristics support its potential clinical application.